Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mecasermin.

Gillian M Keating1

  • 1Wolters Kluwer Health Adis, Auckland, New Zealand. demail@adis.co.nz

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|May 17, 2008
PubMed
Summary
This summary is machine-generated.

Mecasermin, a treatment for growth failure, significantly increased height velocity in children with severe insulin-like growth factor-I (IGF-I) deficiency. This therapy demonstrated sustained growth benefits for up to eight years in clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Afatinib in advanced NSCLC: a profile of its use.

Drugs & therapy perspectives : for rational drug selection and use·2019
Same author

Afatinib in advanced NSCLC: a profile of its use.

Drugs & therapy perspectives : for rational drug selection and use·2018
Same author

Ticagrelor: A Review in Long Term Secondary Prevention of Cardiovascular Events.

Drugs·2017
Same author

Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome.

Drugs·2017
Same author

Sorafenib: A Review in Hepatocellular Carcinoma.

Targeted oncology·2017
Same author

Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex<sup>®</sup>): A Review in Multiple Sclerosis-Related Spasticity.

Drugs·2017
Same journal

Ustekinumab Biosimilars versus Reference Ustekinumab for Moderate-to-Severe Plaque Psoriasis: A Pre-switch Systematic Review and Meta-analysis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Correction: Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Review of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose Adalimumab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

An Overview and Trend Analysis of Biosimilar Approvals in China.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
See all related articles

Area of Science:

  • Pediatric Endocrinology
  • Growth Hormone Therapy
  • Metabolic Disorders

Background:

  • Mecasermin (recombinant human insulin-like growth factor-I [IGF-I]) is approved for treating growth failure in specific pediatric populations.
  • Severe primary IGF-I deficiency or GH gene deletion with neutralizing GH antibodies are key indications.
  • Growth hormone insensitivity (GHI) is a condition where the body does not respond properly to growth hormone.

Purpose of the Study:

  • To evaluate the efficacy of subcutaneous mecasermin in promoting linear growth in children with growth failure and severe IGF-I deficiency associated with GH insensitivity.
  • To assess the long-term effects of mecasermin on growth velocity and height standard deviation scores.

Main Methods:

  • A noncomparative, multicenter trial involving 76 children with growth failure and severe IGF-I deficiency.

Related Experiment Videos

  • Treatment involved subcutaneous mecasermin at 0.12 mg/kg twice daily.
  • Growth velocities and height standard deviation scores were monitored over extended periods (mean 4.4 years, up to 12.5 years).

    • Main Results:

    • Subcutaneous mecasermin significantly increased height velocity in the first year of treatment (from 2.8 cm/year to 8.0 cm/year).
    • Sustained growth velocities above baseline were observed for up to 8 years.
    • In a separate trial, mecasermin therapy for 6.5-7.5 years resulted in a mean increase of +1.4 in height standard deviation score.

    Conclusions:

    • Mecasermin effectively stimulates linear growth in children with growth failure due to severe IGF-I deficiency and GH insensitivity.
    • The treatment provides sustained growth benefits over several years.
    • Mecasermin was generally well tolerated in the studied pediatric population.